{"filing":{"accession_number":"0001708599-26-000040","cik":"0001708599","ticker":"SER","company_name":"Serina Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"ser-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000040/ser-20260617.htm"},"events":[{"id":13502,"run_id":11999,"accession_number":"0001708599-26-000040","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Serina Therapeutics held its 2026 Annual Meeting of Stockholders on June 17, 2026, with voting results disclosed covering eight proposals including director elections, authorization of additional common shares, equity plan amendment, preferred stock conversion, private placement securities exercise, say-on-pay votes, and auditor ratification.","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10648,"accession_number":"0001708599-26-000040","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Serina Therapeutics' 2026 Annual Meeting of Stockholders held on June 17, 2026, covering eight proposals including director elections, share authorization increase, equity plan amendment, preferred stock conversion, private placement securities exercise, say-on-pay votes, and auditor ratification. The comprehensive tabulation of votes for and against each proposal is the hallmark of shareholder_vote_results classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:11:44.876537+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":13503,"run_id":11999,"accession_number":"0001708599-26-000040","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"Stockholders approved an amendment to the Certificate of Incorporation increasing authorized common shares from 40 million to 125 million, a routine administrative action to facilitate future capital raises or equity issuances.","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10647,"accession_number":"0001708599-26-000040","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure describes a routine amendment to the Certificate of Incorporation increasing authorized common shares from 40 million to 125 million, approved by stockholders at the Annual Meeting. While the increase in authorized shares could facilitate future capital raises or equity issuances, the amendment itself is a standard corporate governance action that does not constitute a material event affecting the total mix of information available to investors at the time of disclosure—it is administrative in nature and does not represent an immediate financial or operational change.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:11:44.876537+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10647,"accession_number":"0001708599-26-000040","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure describes a routine amendment to the Certificate of Incorporation increasing authorized common shares from 40 million to 125 million, approved by stockholders at the Annual Meeting. While the increase in authorized shares could facilitate future capital raises or equity issuances, the amendment itself is a standard corporate governance action that does not constitute a material event affecting the total mix of information available to investors at the time of disclosure—it is administrative in nature and does not represent an immediate financial or operational change.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:11:44.876537+00:00","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-06-24"},{"id":10648,"accession_number":"0001708599-26-000040","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Serina Therapeutics' 2026 Annual Meeting of Stockholders held on June 17, 2026, covering eight proposals including director elections, share authorization increase, equity plan amendment, preferred stock conversion, private placement securities exercise, say-on-pay votes, and auditor ratification. The comprehensive tabulation of votes for and against each proposal is the hallmark of shareholder_vote_results classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:11:44.876537+00:00","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-06-24"}]}